Cost-Effectiveness of Sorafenib Versus Selective Internal Radiation Therapy for Patients with Advanced Hepatocellular Carcinoma

被引：0
|
作者：
Parikh, Neehar Dilip [1 ]
Singal, Amit G. [2 ]
Kulik, Laura M. [3 ]
Hutton, David [4 ]
机构：
[1] Univ Michigan, Internal Med, Ann Arbor, MI 48109 USA
[2] Univ Texas Southwestern Med Ctr Dallas, Internal Med, Dallas, TX 75390 USA
[3] Northwestern Med Fac Fdn, Chicago, IL USA
[4] Univ Michigan, Ann Arbor, MI 48109 USA
来源：
HEPATOLOGY | 2018年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
908
引用
收藏
页码：532A / 533A
页数：2
相关论文
共 50 条
  • [31] Efficacy and cost-effectiveness of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Li, Qiu
    Zhang, Pengfei
    Yang, Yu
    Wen, Feng
    Wheeler, Jack
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [32] Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis
    Edeline, Julien
    Crouzet, Laurence
    Campillo-Gimenez, Boris
    Rolland, Yan
    Pracht, Marc
    Guillygomarc'h, Anne
    Boudjema, Karim
    Lenoir, Laurence
    Adhoute, Xavier
    Rohou, Tanguy
    Boucher, Eveline
    Clement, Bruno
    Blanc, Jean-Frederic
    Garin, Etienne
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 (04) : 635 - 643
  • [33] Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis
    Julien Edeline
    Laurence Crouzet
    Boris Campillo-Gimenez
    Yan Rolland
    Marc Pracht
    Anne Guillygomarc’h
    Karim Boudjema
    Laurence Lenoir
    Xavier Adhoute
    Tanguy Rohou
    Eveline Boucher
    Bruno Clément
    Jean-Frédéric Blanc
    Etienne Garin
    European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43 : 635 - 643
  • [34] Sorafenib for advanced hepatocellular carcinoma (HCC) in the public health setting in Brazil: a cost-effectiveness analysis
    Sasse, A.
    Carmo, R.
    ANNALS OF ONCOLOGY, 2019, 30 : 66 - 66
  • [35] Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China
    Shukui Qin
    Eliza Kruger
    Seng Chuen Tan
    Shuqun Cheng
    Nanya Wang
    Jun Liang
    Cost Effectiveness and Resource Allocation, 16
  • [36] Cost-effectiveness analysis of FOLFOX4 and sorafenib for the treatment of advanced hepatocellular carcinoma in China
    Qin, Shukui
    Kruger, Eliza
    Tan, Seng Chuen
    Cheng, Shuqun
    Wang, Nanya
    Liang, Jun
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2018, 16
  • [37] ASSESSING THE ROBUSTNESS OF A COST-EFFECTIVENESS ANALYSIS OF LENVATINIB VERSUS SORAFENIB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA IN JAPAN
    Ikeda, S.
    Kudo, M.
    Izumi, N.
    Kaneko, S.
    Kobayashi, M.
    Azuma, M.
    Copher, R.
    Virabhak, S.
    Mitchell, D.
    Meier, G.
    Ishii, M.
    VALUE IN HEALTH, 2018, 21 : S46 - S46
  • [38] Cost effectiveness of selective internal radiation therapy (SIRT) with Y-90 resin microspheres versus sorafenib in Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma patients in the UK
    Palmer, D.
    Ross, P.
    Shah, T.
    Yu, D.
    Shergill, S.
    Patterson, K.
    Brereton, N.
    Lee, D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [39] Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
    Sanoff, Hanna K.
    Chang, YunKyung
    Lund, Jennifer L.
    O'Neil, Bert H.
    Dusetzina, Stacie B.
    ONCOLOGIST, 2016, 21 (09): : 1113 - 1120
  • [40] Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma in Spain
    Maroto, P.
    Villavicencio, H.
    Pinol, C.
    Urruticoechea, L.
    VALUE IN HEALTH, 2006, 9 (06) : A280 - A280
12345